Zacks Investment Research on MSN

Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?

Black Diamond Therapeutics, Inc. BDTX is developing MasterKey therapies that target families of oncogenic mutations in ...
ascopubs.org

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials

Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review FGFRi are effective treatment strategies for patients with advanced ...
Los Angeles Times

How Growth Factors Are Transforming Anti-Aging Skincare

LA Times Studios may earn commission from purchases made through our links. If you continually chase every so-called “miracle” ingredient (retinol, vitamin C, hyaluronic acid), you’re not alone.

BDTX Stock Hits 52 Week High: Is There More Room for Growth?

Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
ascopubs.org

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...